Vicore Pharma Holding AB Sponsored ADR (VCRE) Live Share Price, Invest From India

Vicore Pharma Holding AB Sponsored ADR Stock Performance

as on August 19, 2026 at 6:59 am IST

Day's Low
Day's High
$11.93
Day's Price Range
$12.50
$11.91
-0.17%
Downside
4.95%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$11.91
100.00%
Downside
-100.00%
Upside

Vicore Pharma Holding AB Sponsored ADR share price movements today

Previous Close: $12.23
Open: $11.94
Volume: 155.9K
Market Cap: $364.0M
Day's Low - High: $11.93 - $12.50

Vicore Pharma Holding AB Sponsored ADR Historical Returns

1 Month Return: + 9.39 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Vicore Pharma Holding AB Sponsored ADR Stock Fundamentals & Key Indicators

Check Vicore Pharma Holding AB Sponsored ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$364.0M

EPS (TTM)

-1.65

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-47.19%

Vicore Pharma Holding AB Sponsored ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vicore Pharma Holding AB Sponsored ADR with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Vicore Pharma Holding AB Sponsored ADR	NA	$364.0M	NA	NA	0.00%	NA
Revolution Medicines	BUY	$43.7B	669.3%	NA	0.00%	NA
Vertex Pharmaceuticals	BUY	$128.2B	154.86%	29.82	86.04%	NA
Regeneron	BUY	$82.7B	24.1%	19.24	84.86%	0.44999999999999996%

Indian Investors' Interest in Vicore Pharma Holding AB Sponsored ADR Stock

Search interest for Vicore Pharma Holding AB Sponsored ADR Stock has decreased by -61% in the last 30 days, reflecting a downward trend in search activity.

Time period: July 20, 2026 to August 19, 2026

Change:-61% versus previous 30 day period

Vicore Pharma Holding AB Sponsored ADR Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Total Revenue	0	0	1	0	0
Gross Profit	0	0	1	0	0
Operating Income	-94	-91	-111	-133	-123
EBITDA	-	-	-	-	-
Interest Expense	0	26	14	8	0
Depreciation	-	-	-	-	-
Income Before Tax	-84	-111	-115	-137	-108
Income Tax Expense	-	-	-	-	-
Net Income	-7	-11	-115	-137	-108
Net Profit Margin	-1647.56%	-12503.92%	-6607.27%	-32721.48%	-18042.52%

Vicore Pharma Holding AB Sponsored ADR Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	9	3
Gross Profit	-	-	9	3
Operating Income	-287	-320	-190	-454
EBITDA	-	-	-	-
Interest Expense	0	0	0	0
Depreciation	3	3	2	-
Income Before Tax	-288	-311	-168	-477
Income Tax Expense	-	-	-	-
Net Income	-27	-30	-15	-477
Net Profit Margin	0.00%	0.00%	-154.22%	-12509.14%

Vicore Pharma Holding AB Sponsored ADR Quarterly Cash Flow

All numbers in Millions USD

	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-111	-115	-113	-137	-108
Operating Cash Flow	-86	-106	-	-81	-117
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-
Change in Cash	-419	-356	-	111	-206

Vicore Pharma Holding AB Sponsored ADR Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-310	-168	-477
Operating Cash Flow	-249	-164	-375
Investing Cash Flow	-	-	-
Financing Cash Flow	-	-	-
Change in Cash	76	818	-545

Insights on Vicore Pharma Holding AB Sponsored ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, VCRE stock has moved up by 2.7%

About Vicore Pharma Holding AB Sponsored ADR

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Organisation	Vicore Pharma Holding AB Sponsored ADR
Headquarters	Kornhamnstorg 53, Stockholm, Sweden, 111 27
Industry	Biotechnology
CEO	Mr. Ahmed S. Mousa J.D.
E-voting on shares	Click here to vote

Key Management of Vicore Pharma Holding AB Sponsored ADR

Name	Title
Mr. Karam Hijji	General Counsel
Mr. Ahmed S. Mousa J.D.	Chief Executive Officer
Mr. Hans Jeppsson Ph.D.	Chief Financial Officer
Ms. Helen Barker	Chief Technology Officer
Ms. Megan Richards	VP of Investor Relations, Communications & Portfolio Strategy
Mr. Jimmie Hofman	Chief Business Officer
Mr. Mikael Nygård	Chief Operating Officer
Dr. Rob Slack Ph.D.	Chief Scientific Officer
Ms. Nina Carlen	Chief Administrative Officer
Ms. Johanna Grans Ph.D.	Head of Non-Clinical Development

FAQs

What is Vicore Pharma Holding AB Sponsored ADR share price today?

Vicore Pharma Holding AB Sponsored ADR share price today is $11.91 as on August 19, 2026 at 1:29 am IST at the close of the market. Vicore Pharma Holding AB Sponsored ADR share today touched a day high of $12.50 and a low of $11.93.

What is the 52 week high and 52 week low for Vicore Pharma Holding AB Sponsored ADR share?

Vicore Pharma Holding AB Sponsored ADR share touched a 52 week high of $0.00 on January 1, 1970 and a 52 week low of $0.00 on January 1, 1970. Vicore Pharma Holding AB Sponsored ADR stock price today i.e. August 19, 2026 at 1:29 am IST is closed at $11.91,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Vicore Pharma Holding AB Sponsored ADR's market capitalisation today?

Vicore Pharma Holding AB Sponsored ADR market capitalisation is $0.00T as on August 19, 2026 at 1:29 am IST.

How to invest in Vicore Pharma Holding AB Sponsored ADR Stock (VCRE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Vicore Pharma Holding AB Sponsored ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vicore Pharma Holding AB Sponsored ADR Shares that will get you 0.1259 shares as per Vicore Pharma Holding AB Sponsored ADR share price of $11.91 per share as on August 19, 2026 at 1:29 am IST.

What is the minimum amount required to buy Vicore Pharma Holding AB Sponsored ADR Stock (VCRE) from India?

Indian investors can start investing in Vicore Pharma Holding AB Sponsored ADR (VCRE) shares with as little as ₹95.67 or $1 (as of August 19, 2026 at 3:37 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.70 in Vicore Pharma Holding AB Sponsored ADR stock (as per the Rupee-Dollar exchange rate as on August 19, 2026 at 3:37 am IST). Based on Vicore Pharma Holding AB Sponsored ADR share’s latest price of $11.91 as on August 19, 2026 at 1:29 am IST, you will get 0.8396 shares of Vicore Pharma Holding AB Sponsored ADR. Learn more about fractional shares .